Trial Profile
A phase Ib/II combination trial of PU-H71 in patients with myelofibrosis
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Zelavespib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Samus Therapeutics
- 06 Apr 2017 New trial record
- 30 Mar 2017 According to a Samus Therapeutics media release, the company expects to file an Investigative New Drug (IND) application for PU-H71 in the treatment of myelofibrosis in the second quarter of 2017.